Portfolio company
Graybug Vision
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops sustained-release injectable medicines for patients with retinal diseases and glaucoma to reduce the frequency of ocular treatments.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
INEYE Therapeutics
This company develops ocular drug delivery inserts to treat chronic eye conditions such as dry eye and glaucoma for patients.
Perfuse Therapeutics
The company develops sustained-release intravitreal therapies to treat ischemia-driven ocular diseases for patients with conditions like glaucoma and diabetic retinopathy.
SpyGlass Pharma, Inc
The company develops an intraocular lens drug delivery system for patients with glaucoma to provide long-term medication during cataract surgery.
Envisia
This clinical-stage biotechnology company develops extended-release ocular therapies for patients with glaucoma and other eye disorders.
Tavo Biotherapeutics
The company develops topical and injectable treatments for patients with glaucoma and retinal diseases.
Eyconis
The company develops long-acting ophthalmic medicines for patients with retinal diseases such as wet age-related macular degeneration.
Adverum Biotechnologies
The company develops ocular gene therapies to treat retinal diseases for patients with vision-threatening conditions such as wet age-related macular degeneration.
Iveric Bio
This biopharmaceutical company develops therapeutic treatments for retinal diseases and provides these medicines to patients with age-related macular degeneration and inherited conditions.